Navigating the Complexities of Ph Negative ALL - Part XIII

Speciality: Oncology


Speaker:

Dr. Sumeet Mirgh | Assistant Professor - Adult Hematolymphoid and BMT

Dr. Nitin Gupta | Sr. Consultant - Hematology

Dr. Anshul Gupta | Assistant Professor - Clinical Hematology

Dr. Bhaarat Folbs | Consultant Hemato-Oncologist

Dr. Shinto Francis | Sr. Consultant - Hemato-Oncologist

Description:

A warm welcome to all the medical professionals in this exciting learning session on managing Ph negative Acute lymphoblastic leukemia in adults.

Acute Lymphoblastic Leukemia (ALL) is a cancer of the blood and bone marrow that progresses rapidly without treatment. It can reoccur after being in remission from previous treatment. It has been noted that refractory ALL did not respond to treatment indicating the previous treatments did not kill enough leukemia cells (blasts) to reach complete remission.

Ph-positive ALL is a special type of ALL in which a genetic mutation is observed in the Philadelphia chromosome. In the case of Ph-negative ALL, genetic disparities are also observed and most importantly in Ph neg ALL there is a disproportionate survival rate among the patients.

Managing Ph neg ALL often becomes difficult, however, the procedures of management of Philadelphia chromosome (Ph)–negative acute lymphoblastic leukemia (ALL) have changed dramatically in recent years leading to a positive vibe for the situation.
 
Therefore,  have overall knowledge regarding the management of Ph negative ALL. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Advances in "next generation" photoactive cancer therapy

2.

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

3.

The American College of Physicians updated its recommendations for colorectal cancer screening.

4.

Optimizing Sequencing of BCMA-Directed Therapies in Myeloma

5.

According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot